Botanical species · safety record

Rubus chingii

The EFSA Compendium of Botanicals holds 14 constituent measurements and 1 adverse-effect record for Rubus chingii. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Rubus chingii var. suavissimus (S.K.Lee) L.T.Lu

14Constituent measurements

1Safety records

9Cited sources

109Licensed products (Canada)

Also recorded as

Rubus suavissimus S.K.Lee

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 109 licensed products naming Rubus chingii as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
decoction

Source material stated

Aged bark
Fruit
Fruit extract
Fruit(s)
Prepared root

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
4-hydroxybenzaldehyde	Unspecified	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Alkaloids	Fruit unspecified	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Ellagitannins (hydrolysable tannins)	Leaves	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Gallic acid	Leaves	Solvent extraction	≥ 0.104 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Gallic acid	Leaves	Solvent extraction	≤ 0.162 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Gallic acid	Leaves	Solvent extraction	1.6 Percent	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Indole alkaloids	Fruit unspecified	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Quinoline alkaloids	Fruit unspecified	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Gallic acid	Fruit unspecified	Solvent extraction	≤ 104.8 Microgram/millilitre	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Gallic acid	Roots and other underground parts	Solvent extraction	≥ 4.082 Microgram/millilitre	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Gallic acid	Roots and other underground parts	Solvent extraction	≤ 40.815 Microgram/millilitre	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Gallic acid	Fruit unspecified	Solvent extraction	≥ 5.24 Microgram/millilitre	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Phenylpropanoids	Fruit unspecified	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Salicylic acid	Fruit unspecified	Solvent extraction	—	Colorimetry, Spectroscopy (Spectrometry) and Photometry	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Digestive	Digestive: pancreas	Leaves	Solvent extraction	—	In vitro	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Du, Long-fei., Li, Jie., Yang, Long., He, Ying., Chai, Xin., Zhang, Peng., Wang, Yue-fei. Chemical constituents from the fruits of rubus chingii Hu. Tianran chanwu yanjiu yu kaifa, 2014, p. 1957-1960.
Li, Haizhou., Tanaka, Takashi., Zhang, Ying-Jun., Yang, Chong-Ren., Kouno, Isao. Rubusuaviins a-f, monomeric and oligomeric ellagitannins from chinese sweet tea and their alpha-amylase inhibitory activity . Chemical & pharmaceutical bulletin, 2007, vol. 55, no. 9, p. 1325-1331. DOI
Chou, Guixin., Xu, Shun-Jun., Liu, Dong., Koh, Gar Yee., Zhang, Jian., Liu, Zhijun. Quantitative and Fingerprint Analyses of Chinese Sweet Tea Plant (Rubus suavissimus S. Lee) . Journal of agricultural and food chemistry, 2009, vol. 57, no. 3, p. 1076-1083. DOI
Li, Tian-ao., Tan, Xi-ying. Quantitative determination of gallic acid in Fructus Rubi by HPLC. Zhongguo xiandai yingyong yaoxue, 2008, p. 235-237.
Wu, Xuzhen. Extraction technology optimization and content determination of gallic acid in roots of Rubus chingii Hu from eastern China. Zhongguo yaoshi (wuhan, china), 2015, p. 684-686.
Ding, Hsiou-Yu. Extracts and Constituents of Rubus chingii with 1,1-Diphenyl-2-picrylhydrazyl (DPPH) Free Radical Scavenging Activity. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2011, vol. 12, no. 6, p. 3941-3949. DOI
Liu, Zhijun., Schwimer, Joshua., Liu, Dong., Lewis, James., Greenway, Frank L., York, David A., Woltering, Eugene A. Gallic acid is partially responsible for the antiangiogenic activities of Rubus leaf extract . Phytotherapy research, 2006, vol. 20, no. 9, p. 806-813. DOI
Guo Qi-lei., Yang Jun-Shan. Studies on chemical constituents in fruit of Rubus chingii. Zhongguo zhongyao zazhi, 2005, vol. 30, no. 3, p. 198-200.
You, M.-T., Li, Y.-K., Guo, M.-L. Study on chemical constituents of methylene chloride extract of Rubus chingii. Academic journal of second military medical university, 2009, vol. 30, no. 10, p. 1199-1202. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature